GLYC earnings call for the period ending June 30, 2019.
News & Analysis: GlycoMimetics
GLYC earnings call for the period ending March 31, 2019.
GLYC earnings call for the period ending December 31, 2018.
GLYC earnings call for the period ending June 30, 2018.
Despite good news about its lead drug, investors are rushing for the exits.
A wholly owned cancer drug could eventually reshape an important indication, and a new sickle-cell disease drug could be heading to the FDA as soon as next year.
Updated data that was presented at a key blood conference is exciting investors.
New data from a trial evaluating one of its most promising drug candidates failed to impress investors.
The stock received yet another piece of good news this month -- this time, from Europe.
Optimism over a mid-stage leukemia drug in development is causing shares to climb this week.